Abstract
e15671Background: The oxaliplatin-based therapy administerated over 6 months remains the standard of adjuvant treatment for stage III colon cancer patients.The IDEA study demonstrated that in certa...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
